celecoxib oral / Generic mfg. - LARVOL DELTA

Exploring the Anti-Inflammatory Potential of Saudi Propolis Through Phytochemical Characterization, Molecular Docking, and Dynamic Simulation. (PubMed, Pharmaceutics) - "P3 also exhibited potent and selective COX-2 inhibition with an IC50 of 6.19 ± 0.21 µg/mL (relative to celecoxib, IC50 0.681 ± 0.02 as positive control)... Saudi propolis P3 is a potent source of bioactive compounds with strong antioxidant and selective COX-2 inhibitory activity. These findings highlight its anti-inflammatory potential and suggest its value as a natural lead for developing safer therapeutics targeting inflammation-related chronic diseases."

Journal • Inflammation

On the road to personalized therapy: 3D-printed nanostructured orodispersible films for repurposed anticancer drug delivery in pediatric oncology. (PubMed, Int J Pharm) - "The aim of this study was to develop and characterize a three-dimensional (3D)-printed orodispersible film (ODF) using semi-solid extrusion (SSE), intended for the administration of pimavanserin (PIMA) and celecoxib (CXB), selected as repurposed anticancer agents, previously encapsulated in nanostructured lipid carriers (NLCs), for pediatric oncology. Infill density also strongly affected drug release: at 120 min, PIMA release ranged from 44% (100% infill) to over 97% (50% infill), showing that infill modulation alone enables predictable adjustment of dose, disintegration, and release kinetics without altering ink composition. This study reports the first formulation that combines pre-encapsulated PIMA and CXB in NLCs within a 3D-printed ODF using SSE, thereby constituting a promising platform for personalized pediatric drug delivery."

Journal • Oncology • Pediatrics

Combined in vitro microcurrent stimulation and celecoxib suppress NF-κB/NLRP3 signaling and cartilage catabolism in human chondrocytes. (PubMed, Immunol Res) - "Selected treatment responses were reproduced in primary human knee articular chondrocytes. Controlled in vitro microcurrent stimulation combined with celecoxib produced concentration- and current-specific Bliss synergy for IL-6 inhibition and enhanced selected inflammatory and matrix-protective responses. These findings support further evaluation in physiologically relevant cartilage and in vivo osteoarthritis models but should not be interpreted as evidence of clinical efficacy or equivalence to clinical electroacupuncture."

Journal • Preclinical • Immunology • Osteoarthritis • Pain • Rheumatology • COL2A1 • IL1B • MMP13 • MYD88 • NLRP3

Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702. (PubMed, J Natl Cancer Inst) - "Greater physical activity was associated with improved DFS among patients who were ctDNA-negative. Physical activity and adjuvant celecoxib was associated with favorable survival outcomes regardless of ctDNA status."

Journal • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Serplulimab Combined with CAPOX and Celecoxib as Neoadjuvant Therapy for Proficient Mismatch Repair Locally Advanced Mid-to-Low Rectal Cancer (SCAR) (ESMO 2026) - No abstract available

Clinical • Metastases • Mismatch repair • pMMR • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

Successful Endoscopic Band Ligation for Bleeding Duodenal Lymphangiectasias and Transfusion-Dependent Anemia (ACG 2026) - "She notably was taking celecoxib for a recent shoulder surgery...EGD at an outside institution showed a site of oozing in the 3rd portion of the duodenum, suspicious for a varix which was cauterized and injected with epinephrine...Figure: Figure 2: Interval improvement of duodenal lymphangiectasias after banding treatments. Photo A depicts pre-treatment, Photo B is one month after the first banding session, Photo C is one month after the second banding session, and Photo D is three months after the third and final banding treatment."

Anemia • Hematological Disorders • Varicose Veins

Chlorogenic acid attenuates LPS-induced hepatic oxidative stress in broilers by regulating cyclooxygenase-2 expression. (PubMed, Poult Sci) - "Immune stress can impair growth performance and induce hepatic oxidative injury; however, the protective potential and underlying mechanisms of the dietary phenolic compound chlorogenic acid (CGA) remain unclear. Celecoxib partially reproduced the effects of CGA by reducing PTGS2 and NOX1 expression and increasing FoxO3 expression. Collectively, CGA alleviates LPS-induced hepatic oxidative stress and partially improves growth performance, potentially by suppressing a COX-2-associated NOX1-mediated pro-oxidant response and enhancing Nrf2/FoxO3/GPX1-dependent antioxidant defenses."

Journal • FOXO3 • GPX1 • PACERR • PTGS2

Randomised comparative effectiveness trial evaluating the efficacy and safety of acupuncture-related integrative therapy combined with celecoxib for chronic pain in patients with knee osteoarthritis: protocol. (PubMed, BMJ Open) - "Registered on 5 December 2025. The first participant was recruited on 27 February 2026."

Clinical protocol • HEOR • Journal • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

OSU-03012 mitigates pulmonary fibrosis by targeting ECM proteins via suppression of S6K-mediated translation and acceleration of MMP-driven clearance. (PubMed, Biomed Pharmacother) - "This study investigated the anti-fibrotic potential and underlying molecular mechanisms of OSU-03012 action, a celecoxib derivative that inhibits Akt activity without targeting cyclooxygenase. Collectively, these findings demonstrate that OSU-03012 exerts potent anti-fibrotic and regressive effects by targeting ECM proteins through the inhibition of ECM component translation and the promotion of ECM degradation. Thus, OSU-03012 represents a novel and promising therapeutic candidate capable of overcoming the critical limitations of current IPF and pulmonary fibrosis treatments."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • TGFB1

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045."

Circulating tumor DNA • Clinical • Journal • P3 data • Retrospective data • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Leukemia • Microsatellite Instability • Oncology • Solid Tumor • MSI • PIK3CA

Neoadjuvant chemokine modulation of the tumor microenvironment (TME) in resectable metastatic colorectal cancer: Results from a phase I study. (ASCO 2026) - P1/2 | "The chemokine-modulating (CKM) regimen, consisting of IFNα, rintatolimod (a selective TLR3 agonist), and celecoxib (a COX-2 inhibitor), also suppresses CCL22, a Treg-attracting chemokine in the TME... Neoadjuvant CKM regimen is safe and feasible in resectable metastatic CRC and is associated with improved ratios of CD8+ CTLs to FoxP3+ Tregs in the TME. Further studies combining CKM with immune checkpoint inhibitors and/or chemotherapy are warranted to evaluate the impact of preoperative TME modulation on long-term oncologic outcomes in CRC."

Biomarker • Clinical • IO biomarker • Metastases • P1 data • Tumor microenvironment • Colorectal Cancer • Immune Modulation • Immunology • Leukopenia • Neutropenia • Oncology • Solid Tumor • CCL2 • CCL22 • CD8 • CXCL10 • CXCL11 • CXCL9 • FOXP3 • IFNA1

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). (PubMed, J Clin Oncol) - "Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greatest improvements in DFS."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702. (ASCO-GI 2025) - P3 | " In the subset of patients with adequate biospecimens who participated in CALGB/SWOG 80702, a randomized phase III trial of 3 versus 6 months of adjuvant 5-FU, leucovorin, oxaliplatin (FOLFOX) +/- celecoxib, ctDNA assessment was performed using a clinically validated, tumor-informed 16-plex mPCR-NGS assay (Signatera(TM), Natera, Inc.) after surgery and before the start of adjuvant therapy (baseline)... In a randomized phase III adjuvant therapy trial for stage III colon cancer, ctDNA was highly prognostic of DFS and OS. ctDNA positivity also appeared predictive of the benefit of adjuvant celecoxib for DFS and OS. These results suggest a potential role for ctDNA in determining which patients should consider celecoxib in addition to standard FOLFOX adjuvant therapy."

Circulating tumor DNA • Late-breaking abstract • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Efficacy of celecoxib and methotrexate-vinblastine regimen in desmoid-type fibromatosis: A retrospective cohort study. (PubMed, Medicine (Baltimore)) - "Although tumor progression occurred in the remaining cases, disease control was subsequently achieved by introducing the MV regimen. These findings support recent trends favoring nonsurgical management and suggest that the celecoxib followed by the MV regimen strategy should be considered a primary therapeutic approach."

Journal • Retrospective data • Desmoid Tumors • Fibrosis • Oncology • Sarcoma • Solid Tumor

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. (PubMed, Nat Med) - P2 | "In the exploratory NICHE study (ClinicalTrials.gov: NCT03026140), patients with dMMR or pMMR tumors received a single dose of ipilimumab and two doses of nivolumab before surgery, the pMMR group with or without celecoxib. CD8PD-1 T cell infiltration was predictive of response in pMMR tumors. These data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data."

Clinical • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. (PubMed, J Clin Oncol) - "Lower physical activity, higher BMI, diabetes, and longer planned treatment duration, but not celecoxib use or vitamin B6 intake, may be associated with significantly increased OIPN severity."

Journal • Colon Cancer • Colorectal Cancer • Diabetes • Gastrointestinal Cancer • Metabolic Disorders • Oncology • Pain • Solid Tumor

Combinatorial delivery of low-dose radiotherapy and immunotherapy to patients with immune-excluded tumors enhances CD8+ T cell functionality. (PubMed, Clin Cancer Res) - "These findingssuggest that LDRT combined with ICB is safe and may contribute to immunomodulatory activity in immune-excluded tumors. CD8⁺ TIL dynamics, DNA repair responsiveness, and TME composition may predict response and merit further validation in controlled larger studies."

Journal • Oncology • Ovarian Cancer • Solid Tumor • CD8 • PD-1

Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. (ASCO 2022) - P2 | "These data confirm our previously published results of the NICHE study, with responses to neoadjuvant nivolumab plus ipilimumab in 30% of pMMR and 100% of dMMR CC in the completed original cohorts. Validation of the dMMR responses in a large group of dMMR patients is ongoing and has the potential to change current practice."

Clinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Immunology • Myositis • Oncology • Solid Tumor

Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial. (PubMed, Lancet Oncol) - P2 | "In patients with dMMR or MSI-H locally advanced colorectal cancer, neoadjuvant toripalimab plus celecoxib significantly increased the proportion of patients attaining pathological complete response compared with toripalimab monotherapy, with a similar safety profile. These findings support further investigation of this combination strategy in larger phase 3 trials."

dMMR • Journal • Mismatch repair • Monotherapy • MSI-H • P2 data • Colorectal Cancer • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Microsatellite Instability • Oncology • Solid Tumor • MSI

Effectiveness and multidimensional mechanisms of close-to-bone needling in knee osteoarthritis: a randomized controlled trial. (PubMed, Am J Transl Res) - "CBN represents an effective non-pharmacological intervention for KOA, with advantages over celecoxib in symptom relief, joint structure improvement, molecular regulation, and central neural normalization. The proposed "brain-molecule-clinic" assessment framework provides multidimensional evidence supporting the potential mechanisms of acupuncture-based interventions in KOA."

Journal • CNS Disorders • Immunology • Musculoskeletal Diseases • Oncology • Osteoarthritis • Pain • Rheumatology • IL1B • MIR140 • TNFA

Preoperative photobiomodulation versus nonsteroidal anti-inflammatory drugs for pain and early functional recovery after total knee arthroplasty: a randomized controlled trial. (PubMed, Front Cell Dev Biol) - "PBMT was associated with smaller increases in thigh circumference on postoperative days 3 and 7, less hidden blood loss, and fewer reports of gastrointestinal discomfort. Preoperative 810 nm semiconductor-laser PBMT met the stated non-inferiority criterion for 24-h resting pain compared with celecoxib and was associated with favorable swelling, blood-loss, and gastrointestinal outcomes."

Journal • Cardiovascular • Gastrointestinal Disorder • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Loss of sTREM2 exacerbates silver nanoparticle-induced ferroptosis driven by microglia-mediated neuroinflammation: In vivo and in vitro evidence. (PubMed, Int Immunopharmacol) - "Exogenous sTREM2 supplementation, the NF-κB inhibitor PDTC, or the COX-2 inhibitor celecoxib each alleviated neuroinflammation, restored redox balance, and reversed ferroptosis. Collectively, these findings provide in vivo and in vitro correlational evidence that that sTREM2 deficiency is associated with aggravated AgNPs-induced ferroptosis through microglia-driven neuroinflammatory activation. This study provides reliable experimental evidence for establishing an adverse outcome pathway (AOP) framework for AgNP-induced neurotoxicity and for developing related immunomodulatory intervention strategies."

Journal • Preclinical • Inflammation • TREM2

Design, synthesis, structure-activity relationship and in-silico studies of novel pyrazolo[1,5-a]pyrimidine derivatives as selective COX-2 inhibitors with promising anti-inflammatory activity and safety profile. (PubMed, Bioorg Chem) - "Nine representative compounds spanning both high- and low-selectivity chemotypes were evaluated in a formalin-induced paw edema model, chosen over carrageenan for its chronic, biphasic inflammatory profile: 8a displayed 1.5-fold higher potency than indomethacin and 1.45-fold over celecoxib (p < 0.0001), while 8i achieved 1.25-1.30-fold and 1.6-fold relative potency (p < 0.01). Molecular docking, 100 ns MD simulations, and MM-GBSA binding free energy calculations further confirmed stable active-site binding (ΔGbind = -54.32 and - 56.14 kcal/mol for 8a and 8i, respectively). Collectively, these integrated results establish 8a and 8i as potent, selective, and structurally stable lead candidates for preclinical COX-2 inhibitor development."

Journal • IL6

Antimicrobial and Anti-Inflammatory Co-Loaded Chitosan/Polyvinyl Alcohol Hydrogel for Synergistic Treatment of Diabetic Wounds. (PubMed, J Biomed Mater Res B Appl Biomater) - "To develop a chitosan/polyvinyl alcohol (CS/PVA) hydrogel co-loaded with polyhexamethylene biguanide (PHMB) and celecoxib (CEL) for synergistic treatment of diabetic foot ulcers (DFUs)...The CEL/PHMB/CS/PVA composite hydrogel promotes the healing of diabetic wounds through the synergistic effects of PHMB's antibacterial action and CEL's anti-inflammatory action. The hydrogel demonstrates good biosafety and potential for clinical translation."

Journal • Diabetes • Hematological Disorders • Inflammation • Type 1 Diabetes Mellitus • CD31 • IL1B • IL6 • MRC1 • PECAM1

A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - P1 | N=202 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology